Iloprost, a stable prostacyclin analogue, is being investigated for its potential to enhance insulin sensitivity and glucose uptake in patients with Type 2 diabetes. Given the increasing prevalence of diabetes and the need for effective treatments, this study could position iloprost as a novel therapeutic option in a competitive market dominated by existing antidiabetic medications. The results may provide insights into iloprost's utility in improving metabolic outcomes, which could attract interest from pharmaceutical companies looking to expand their diabetes portfolios. However, the exclusion of patients with cardiovascular events may limit the generalizability of findings, necessitating further studies to confirm efficacy and safety in broader populations.